This trial compares the effectiveness of two methods of cancer diagnosis- through studying tissue, and through studying liquid biopsies (blood).
2 Primary · 6 Secondary · Reporting Duration: 24 months
Awards & Highlights
3 Treatment Groups
Simultaneous - no additional testing
1 of 3
Simultaneous - FoundationOne liquid CDx
1 of 3
Sequential - FoundationOne liquid CDx
1 of 3
1500 Total Participants · 3 Treatment Groups
Primary Treatment: FoundationOne liquid CDx · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the scope of this clinical research regarding patient participants?
"Affirmative. Records from clinicaltrials.gov demonstrate that this research project, which was initially uploaded on June 18th 2021, is actively enrolling participants. The trial requires 1500 patients to be recruited across 1 location." - Anonymous Online Contributor
Is the enrollment window still open for this investigation?
"Clinicaltrials.gov affirms that this research is actively enrolling patients, with the trial posted on June 18th 2021 and its content most recently updated as of August 4th 2022." - Anonymous Online Contributor
What are the intended outcomes of this research?
"This trial, which will be measured over a 12 months period of time, is aiming to quantify the number of patients who have an actionable sequencing result upon receiving uninformative standard care oncopanel results. The secondary objectives include evaluating clinical utility through concordance/discordance findings and treatments, as well as gauging the impact FoundationOne liquid CDx has on patient diagnostic pathways by measuring how many repeat biopsies are needed for molecular characterization purposes." - Anonymous Online Contributor